

# Becker Muscular Dystrophy Therapeutic Pipeline Market Review, H2 2016

*Becker Muscular Dystrophy Global Market 2016  
Analysis and Forecast to 2021*

PUNE, INDIA, September 26, 2016  
/EINPresswire.com/ --

The report provides comprehensive information on the therapeutics under development for [Becker Muscular Dystrophy](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects.

Complete Report @  
<https://www.wiseguyreports.com/reports/64978-8-becker-muscular-dystrophy-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy
- The report reviews pipeline therapeutics for Becker Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities



- The report reviews key players involved Becker Muscular Dystrophy therapeutics and enlists all their major and minor projects
- The report assesses Becker Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/649788-becker-muscular-dystrophy-pipeline-review-h2-2016>

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Becker Muscular Dystrophy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Becker Muscular Dystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ <https://www.wiseguyreports.com/enquiry/649788-becker-muscular-dystrophy-pipeline-review-h2-2016>

#### Table of Content

Therapeutics Development	7
Pipeline Products for Becker Muscular Dystrophy - Overview	7
Becker Muscular Dystrophy - Therapeutics under Development by Companies	8
Becker Muscular Dystrophy - Pipeline Products Glance	9
Late Stage Products	9
Clinical Stage Products	10
Early Stage Products	11
Becker Muscular Dystrophy - Products under Development by Companies	12
Becker Muscular Dystrophy - Companies Involved in Therapeutics Development	13
Milo Biotechnology LLC	13
PTC Therapeutics, Inc.	14
ReveraGen BioPharma, Inc.	15
Sarepta Therapeutics, Inc.	16
Sphaera Pharma Pvt. Ltd.	17
Becker Muscular Dystrophy - Therapeutics Assessment	18
Assessment by Monotherapy Products	18
Assessment by Target	19
Assessment by Mechanism of Action	21
Assessment by Route of Administration	23
Assessment by Molecule Type	25
Drug Profiles	27
AAV1-Foliistatin - Drug Profile	27
Product Description	27
Mechanism Of Action	27

R&D Progress 27

Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

ARM-210 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

ataluren - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

epicatechin - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule for Becker Muscular Dystrophy - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

vamorolone - Drug Profile 42

Buy now @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=649788](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649788) □

Continued...

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK) □

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.